Treatment with naringenin also increases the pool of GSH and the activities of glutathione peroxidase, glutathione reductase, glutathione-S-transferase, SOD, and choline acetyltransferase in the hippocampus in a rat model of Alzheimer's disease- (AD-) type neurodegeneration with cognitive impairment (AD-TNDCI), with a concomitant decrease in the loss of ChAT-positive neurons and impairments in spatial learning and memory [102]. The gene discussed is CHAT; the disease is early-onset autosomal dominant Alzheimer disease.